Therapeutic effect of nebulized human recombinant interferon α1b on severe hand-foot-mouth disease children with early study of nervous system complications

Abstract

Objective To evaluate the efficacy and safety of nebulized recombinant human interferon α1b (IFN-α1b) for severe hand-foot-mouth disease(HFMD)children with central nervous system complications (CNSC). Methods This was a multi-center, prospective, cohort study.Severe HFMD children with CNSC from 3 hospitals were assigned to the control group with conventional therapy, and therapeutic group based on convetional therapy with nebulization of recombinant human IFN-α1b, 30 μg twice each day, for 5-7 days.The curative effect between 2 groups was compared by using SPSS 17.0 software. Results Sixty-six cases were enrolled from May to November 2013.Compared with conventional therapy, the treatment of nebulized IFN-α1b could significantly reduce the duration of fever[treatment group (1.9±1.1) d vs control group (2.7±1.2) d, P<0.05 ], the recovery time of food intake[treatment group (3.9±1.4) d vs control group (4.9±1.6) d, P<0.05] and the duration of the central nervous system syndrome[(2.6±1.1) d vs (3.2±1.0) d, P<0.05], especially shorten the duration of convulsion[treatment group (2.4±1.0) d vs control group (3.2±0.9) d, P<0.05]and myoclonic jerk[(2.0±1.1) vs (2.9±1.2) d, P<0.05]. Vital signs, routine hematological and biochemical parameters were monitored and no adverse effect was observed during the treatment. Conclusion Nebulization of human recombinant IFN-α1b can significantly and safely alleviate early clinical syndrome of severe HFMD children. Key words: Nebulization; Hand- foot-mouth disease; Human recombinant interferon α1b; Nervous system complications